title: Effects of gastric inhibitory polypeptide, vasoactive intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets.
abstract: The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI) at concentrations of 1-1000 nmol/l. Insulin release was enhanced (greater than 50%) by GIP (100-1000 nmol/l) and VIP (1 mumol/l) at 5.6 mmol glucose/l, but not at 16.7 mmol glucose/l. Glucagon release was increased by GIP (100-1000 nmol/l), and by VIP and PHI (1-1000 nmol/l) at both glucose concentrations in a dose-related manner (maximum increases greater than tenfold). Somatostatin release was similarly increased by GIP (10-1000 nmol/l) at both glucose concentrations. Only the highest concentration (1 mumol/l) of PHI tested increased somatostatin release (twofold) at 5.6 mmol glucose/l, whereas PHI and VIP (1-1000 nmol/l) reduced (greater than 37%) somatostatin release at 16.7 mmol glucose/l. PP release was increased (49-58%) by 100-1000 nmol GIP/l, but was not significantly altered by VIP, and was reduced (39-56%) by PHI. The results indicate that GIP, VIP and PHI each stimulate glucagon release in a dose-related manner, but they exert discretely different effects on other islet hormones depending upon the dose and the prevailing glucose concentration.
authors.affiliation: Department of Pharmaceutical Sciences, Aston University, Birmingham.
authors.forename: C J
authors.initials: CJ
authors.lastname: Bailey
authors.forename: L C
authors.initials: LC
authors.lastname: Wilkes
authors.forename: J M
authors.initials: JM
authors.lastname: Conlon
authors.forename: P H
authors.initials: PH
authors.lastname: Armstrong
authors.forename: K D
authors.initials: KD
authors.lastname: Buchanan
mesh_terms: D000818:Animals; D005749:Gastric Inhibitory Polypeptide / Q000494:pharmacology; D005934:Glucagon / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D009924:Organ Culture Techniques; D010187:Pancreatic Hormones / Q000378:metabolism*; D010191:Pancreatic Polypeptide / Q000378:metabolism; D010451:Peptide PHI / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D013004:Somatostatin / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D007328:Insulin; D010187:Pancreatic Hormones; D010451:Peptide PHI; D010455:Peptides; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D005749:Gastric Inhibitory Polypeptide; D010191:Pancreatic Polypeptide; D005934:Glucagon; D005947:Glucose